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Suppression of the human immune system results in an increase in susceptibility to infection 
by various infectious agents. Conditions such as AIDS, organ transplantation and chronic 
renal insufficiency (CRI) are the most important cause of insufficient immune response 
against infections. Long term renal disorders result in uremia, which can suppress human 
immune system. Parasitic infections are one of the most important factors indicating the public 
health problems of the societies. These infections can be more hostile and life threatening in 
susceptible individuals than in the normal people. In these patients some parasitic infections 
such as blastocystiosis, cryptosporidiosis and toxoplasmosis have been reported to be more 
prevalent. This review aimed to give an overview about parasitic infections in patients with 
renal disorders.
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Implication for health policy/practice/research/medical education:
Chronic renal failure is one of the causes of immune suppression. In these patients some parasitic infections such as blastocystiosis, 
cryptosporidiosis and toxoplasmosis have been reported to be more prevalent. This review aimed to give an overview about parasitic 
infections in patients with renal disorders.
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A B S T R A C T
Introduction
By increasing the life expectancy among mankind 
population, subsequent incidence of some chronic  diseases, 
such as chronic renal insufficiency (CRI) is increasing 
(1). CRI itself results some complications, in which renal 
function disturbs. When the renal function lost, body 
cannot sustain equilibrium of electrolytes. Consequently 
uremia may occur (2), which is the result of excess non-
excreted metabolites accumulation, like  urea (3). Natural 
state of immune-depression can cause by uremia and 
subsequent increase in the incidence of infections may 
happen (4,5). Around 48% of deaths in CRI patients are 
associated with these infections (2,6).
Also reduced immune response to various antigens, has 
been detected in patients with chronic kidney disease (CKD) 
who undergoing dialysis treatment (7-15). Additionally, 
it has been found that sepsis-related death is between 
100 and 300-times more frequent in patients undergoing 
hemodialysis comparing to the general population (16).
Intestinal parasitic infections have been considered as 
one of the major public health problems, predominantly 
in developing countries. However, because of some 
immunological conditions such as intentional suppression 
of immune response and also some immunodeficiencies in 
developed countries, some of these parasites have become 
a problematic issue (17). Chronic renal diseases are also 
one of the causes of insufficient immune response to the 
infections (2,18).
Considering the important role of parasitic infections in 
creating complications or deaths in patients with renal 
problems, in this paper parasitic infections in patients with 
chronic renal disease is reviewed.
Intestinal parasites
There are lots of studies indicating higher prevalence 
of intestinal parasitic infections in patients with renal 
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disorders, which some are reviewed. 
From 2006 to 2007 hemodialysis patients of Campo 
Mourão city, Brazil were examined for Blastocystis sp. and 
other intestinal parasites and also the associated diarrhea. 
Thirty three (45.1%) out of 86 hemodialysis patients and 
36 (25.7%) out of 146 control individuals were found to 
be infected by the parasites. The prevalence of intestinal 
parasitic infections in hemodialysis patients has been 
reported significantly higher than the healthy individuals. 
It is suggested that parasitological stool examinations, 
particularly for Cryptosporidium spp. and Blastocystis 
sp., are better to be perform in routine medical follow up 
examinations of hemodialysis patients (19).
In another study the prevalence of amoebiasis caused by 
Entamoeba histolytica/dispar in chronic hemodialysis 
patients has been reported to be about 8% (20). In Turkey 
a study carried out on patients with an end-stage renal 
failure and 150 healthy volunteers. Parasites were found 
in 62 (43.7%) out of 142 dialysis patients and 19 (12.7%) 
out of 150 healthy controls. The most prevalent cause of 
parasitic infection in the dialysis patients were Blastocystis 
sp. (23.9%), Giardia lamblia (8.5%), E. histolytica (2.1%), 
Microsporidia spp. (2.1%), and Cryptosporidium spp. (2.1%) 
(21). Intestinal parasitic infections were more prevalent 
in clinically asymptomatic renal transplant recipients 
than in patients with chronic haemodialysis and healthy 
individuals (22).
Study of Gill et al., in 2013, illustrated that 51.6% of 
hemodialysis patients were infected by intestinal parasites, 
but the prevalence of the infections in control group was 
61.6%. Cryptosporidium antigen was observed only in 
patients with CKD (24.5%),  but not in controls (23). They 
reported prevalence of 24.5% for cryptosporidiosis, which 
was considered to be high, even higher than some of the 
reports from renal transplant recipient patients (24) and 
livestock owners (25,26), which were at risk of infection. 
Their study indicated that patients with CKD were at risk 
of infection with Cryptosporidium spp. (23). 
The prevalence of Cryptosporidium infection in patients 
with end-stage of chronic renal failure was investigated 
and compared to the healthy controls. Fifteen out of 174 
patients with dialysis was positive for Cryptosporidium, 
while none of the controls had the infection. The reported 
prevalence was significantly higher in dialysis patients (27).
In another study prevalence of Cryptosporidium infection 
among renal transplant recipients, patients referred to 
hemodialysis and the control group reported 34.8%, 25% 
and 17.4%, respectively (28). In the study carried out in 
Hamadan city, Iran, the prevalence of cryptosporidiosis has 
been reported 0.55% in renal transplanted patients, which 
is controversial to the previously mentioned studies (24).
Also a very interesting report indicated that the prevalence 
of Cryptosporidium infection was 80% in patients with 
cancer, 25% in diabetics and 35% in dialysis patients (29), 
which are considerably higher than those in the reports 
from general population and diarrheic children (25,30). 
In other studies 11.5% of renal transplant and 3.88% of 
hemodialysis patients were positive for Cryptosporidium 
infection. No positive results were found in the control 
groups (31).
Considering spore-forming protozoa, including: Isospora 
belli, Cryptosporidium parvum, Microsporidia and 
Cyclospora cayetanensis in patients with CKD, it has been 
reported that 33.3% of these patients were infected by 
these parasites (32). In another study, fecal samples of 104 
chronic hemodialysis patients and 140 healthy controls 
were investigated for cryptosporidiosis. The prevalence 
of Cryptosporidium infection observed higher (11.5%) in 
dialysis patients compared to controls (3.6%) (33).
Tissue parasites
Anti-Toxoplasma IgG has been reported in 27.3% and 
3.6% of 205 dialysis patients with renal insufficiency and 
360 healthy controls, respectively (34). In another similar 
study, statistically significant higher prevalence has been 
observed for anti-Toxoplasma IgG and IgM seropositivity 
in hemodialysis patients than controls. So it has been 
recommended that hemodialysis patients should be tested 
for anti-Toxoplasma IgG and IgM using specific serological 
tests in order to prevent the disseminated infection (35).
Other report showed that 36.8% of renal failure patients 
and 10.5% of normal population were seropositive for 
anti-Toxoplasma IgG and IgM. Also 56.7% and 16.7% of 
patients with regular hemodialysis and 69% and 24.1% 
of renal transplanted patients were seropositive for anti-
Toxoplasma IgG and IgM, respectively (36). Higher rates 
of anti-Toxoplasma IgG and IgM, in renal transplanted and 
renal failure patients have also been reported (37,38). In 
another investigation significant higher sero-prevalence of 
toxoplasmosis has been reported in patients with chronic 
renal failure (38.3%) compared to the healthy controls 
(15%) (39).
In a study carried-out in Ahvaz city, southwest of Iran, 
29.3% and 7.9% of hemodialysis patients and 26% and 4% 
of controls were seropositive for anti-Toxoplasma IgG and 
IgM, respectively (40). Also in other work the prevalence 
of anti-Toxoplasma gondii  antibodies in 173 hemodialysis 
patients with CKD and 40 healthy controls were 56.06% 
and 1.73% for hemodialysis patients and 20% and 0% for 
healthy controls, respectively (41). Finally anti-Leishmania 
donovani antibodies among 1500 multiply transfused 
hemodialysis patients was (37%)  and among 1194 volunteer 
blood donors was (9%) (42).
Exoparasites
Demodex folliculorum infestation has been detected in 
25.53% of CKD patients and 18.42% of healthy controls 
(43). Also the D. folliculorum  infection reported in 19.54% 
of dialysis patients and in 10.34% of healthy controls (44). 
The mean mite count in patients with infestation  who were 
in end stage of renal failure was 6.12/cm2 while in normal 
controls it was 0.31/cm2 (45).
Case reports about parasites in patients with renal 
disorders
Case report studies about parasites in patients with renal 
disorders are summarized in Table 1.
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Conclusion 
In conclusion, some parasitic diseases are considered as 
public health problems especially in developing countries 
(37,38,51,52). Patients with chronic kidney diseases 
are susceptible to be infected by some parasites such as 
Blastocystis sp., Cryptosporidium spp., and Toxoplasma 
gondii. Parasitic infections in these patients may make 
their situation much more complicated. Continues 
parasitological monitoring of patients with chronic renal 
failure is recommended for the possible control of the 
infections.
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